SG11202108735QA - Long-acting growth hormone dosage forms with superior efficacy to daily somatropin - Google Patents

Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Info

Publication number
SG11202108735QA
SG11202108735QA SG11202108735QA SG11202108735QA SG11202108735QA SG 11202108735Q A SG11202108735Q A SG 11202108735QA SG 11202108735Q A SG11202108735Q A SG 11202108735QA SG 11202108735Q A SG11202108735Q A SG 11202108735QA SG 11202108735Q A SG11202108735Q A SG 11202108735QA
Authority
SG
Singapore
Prior art keywords
somatropin
daily
long
dosage forms
growth hormone
Prior art date
Application number
SG11202108735QA
Other languages
English (en)
Inventor
Kennett Sprogøe
Original Assignee
Ascendis Pharma Endocrinology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Endocrinology Div A/S filed Critical Ascendis Pharma Endocrinology Div A/S
Publication of SG11202108735QA publication Critical patent/SG11202108735QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11202108735QA 2019-03-04 2020-03-03 Long-acting growth hormone dosage forms with superior efficacy to daily somatropin SG11202108735QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19160459 2019-03-04
PCT/EP2020/055513 WO2020178273A1 (fr) 2019-03-04 2020-03-03 Formes posologiques d'hormone de croissance à action prolongée ayant une efficacité supérieure à une dose de somatropine quotidienne

Publications (1)

Publication Number Publication Date
SG11202108735QA true SG11202108735QA (en) 2021-09-29

Family

ID=65685219

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108735QA SG11202108735QA (en) 2019-03-04 2020-03-03 Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Country Status (10)

Country Link
US (1) US20220088147A1 (fr)
EP (1) EP3934625A1 (fr)
JP (1) JP2022522833A (fr)
CN (1) CN113573698A (fr)
AU (1) AU2020233198A1 (fr)
CA (1) CA3131817A1 (fr)
IL (1) IL285903A (fr)
MX (1) MX2021010286A (fr)
SG (1) SG11202108735QA (fr)
WO (1) WO2020178273A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102608645B1 (ko) * 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
CN114920819A (zh) * 2022-06-16 2022-08-19 修正生物医药（杭州）研究院有限公司 重组人生长激素突变体、其聚乙二醇衍生物、聚乙二醇衍生物的制备方法及其药物用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US8377917B2 (en) 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
EA021222B8 (ru) 2007-06-21 2015-11-30 ИксЭль-ПРОТЕИН ГМБХ Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
PT3050576T (pt) 2008-04-29 2021-06-01 Ascendis Pharma Growth Disorders Div A/S Compostos recombinantes e peguilados da hormona de crescimento humana
WO2011123813A2 (fr) 2010-04-02 2011-10-06 Amunix Operating Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
EP2571510B1 (fr) 2010-05-21 2018-08-08 XL-protein GmbH Polypeptides de bobine aléatoires en proline/alanine biosynthétique
EP2908845A1 (fr) 2012-10-17 2015-08-26 Novo Nordisk Health Care AG Acides aminés acylés par un acide gras pour l'administration d'hormone de croissance
KR102608645B1 (ko) * 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
WO2016079302A1 (fr) * 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Formes galéniques d'hormone de croissance à action prolongée
WO2016109823A1 (fr) * 2015-01-02 2016-07-07 Amunix Operation Inc. Traitement d'un déficit en hormone de croissance pédiatrique avec analogues de l'hormone de croissance humaine

Also Published As

Publication number Publication date
MX2021010286A (es) 2021-09-23
JP2022522833A (ja) 2022-04-20
CA3131817A1 (fr) 2020-09-10
IL285903A (en) 2021-10-31
EP3934625A1 (fr) 2022-01-12
CN113573698A (zh) 2021-10-29
US20220088147A1 (en) 2022-03-24
AU2020233198A1 (en) 2021-09-02
WO2020178273A1 (fr) 2020-09-10

Similar Documents

Publication Publication Date Title
IL285903A (en) Long-acting growth hormone dosage forms with greater efficacy than daily somatropin
IL246550B (en) Harvesting, delivery, spectral modification and delivery of sunlight to shaded areas of plants
IL244769A0 (en) A long-acting human growth hormone conjugate preparation
EP2593084A4 (fr) Formulation liquide d'un conjugué d'hormone de croissance humaine à action prolongée
HK1216617A1 (zh) 用人生長激素類似物治療小兒生長激素缺乏症
EP3603660A4 (fr) Nouvelle application pour facteur de croissance des fibroblastes humains mutants à action prolongée
ZA201506420B (en) Treatment of diabetes mellitus by long-acting formulations of insulins
EP2934085A4 (fr) Dents de rabatteur commandées à double came
HK1244227A1 (zh) 長效生長激素劑型
ZA201205385B (en) Stable growth hormone compounds
IL258126B (en) A pharmaceutical composition containing a growth receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and its uses
EP3678469A4 (fr) Tête de récolte de plante cultivée munie d'un élément de réglage de came sensible au mouvement d'un rabatteur
EP2788014A4 (fr) Utilisation de fragments d'hormone de croissance
GB2557469B (en) Improvements relating to crop harvesting
EP2830649A4 (fr) Formulation liquide de conjugué d'hormone de croissance humaine à action prolongée hautement concentrée
ZA201105419B (en) Stable growth hormone compounds
IL258128A (en) A pharmaceutical composition containing a growth receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and its uses
IL260316A (en) A novel liquid formulation of long-acting human growth hormone conjugate
EP4021446A4 (fr) Composés utiles pour traiter la douleur
FI3876700T3 (fi) Sammalkasvualusta
GB201707797D0 (en) Auxiliary feeder roll applied to a sugar cane harvester
EP3893919A4 (fr) Antagonistes d'hormone de croissance pégylés
HUP1300658A2 (en) Vine-stock form for mechanized regulation of vine crop and yield surface
UA93606U (uk) Застосування п-толуїдиду тіобензойної кислоти як стимулятора росту сільськогосподарських рослин
AU2013903682A0 (en) Hay bale feeder